Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Thierry B. Mauvernay | M | - |
Debiopharm International SA
 Debiopharm International SA Pharmaceuticals: MajorHealth Technology Debiopharm International SA operates as a biopharmaceutical development company with focus on biologics and drug evaluation, licensing and development. It formulates and develops products for the treatment of cancer, endometriosis, uterine fibroids and hepatitis. The company was founded in 1979 and is headquartered in Lausanne, Switzerland. | 23 years |
| Alexandre Maret | M | - |
Debiopharm International SA
Debiopharm International SA Pharmaceuticals: MajorHealth Technology Debiopharm International SA operates as a biopharmaceutical development company with focus on biologics and drug evaluation, licensing and development. It formulates and develops products for the treatment of cancer, endometriosis, uterine fibroids and hepatitis. The company was founded in 1979 and is headquartered in Lausanne, Switzerland. | 19 years |
| Pierre Jullian | M | - |
Debiopharm International SA
Debiopharm International SA Pharmaceuticals: MajorHealth Technology Debiopharm International SA operates as a biopharmaceutical development company with focus on biologics and drug evaluation, licensing and development. It formulates and develops products for the treatment of cancer, endometriosis, uterine fibroids and hepatitis. The company was founded in 1979 and is headquartered in Lausanne, Switzerland. | 6 years |
| Gilbert J. B. Probst | M | 73 |
University of Geneva
| 37 years |
| Jean-Maurice Dumonts | M | - |
Debiopharm International SA
Debiopharm International SA Pharmaceuticals: MajorHealth Technology Debiopharm International SA operates as a biopharmaceutical development company with focus on biologics and drug evaluation, licensing and development. It formulates and develops products for the treatment of cancer, endometriosis, uterine fibroids and hepatitis. The company was founded in 1979 and is headquartered in Lausanne, Switzerland. | 26 years |
| David Luc Deperthes | M | - |
Debiopharm International SA
Debiopharm International SA Pharmaceuticals: MajorHealth Technology Debiopharm International SA operates as a biopharmaceutical development company with focus on biologics and drug evaluation, licensing and development. It formulates and develops products for the treatment of cancer, endometriosis, uterine fibroids and hepatitis. The company was founded in 1979 and is headquartered in Lausanne, Switzerland. | 12 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Constantin Papadimitriou | M | 63 |
University of Geneva
| 4 years |
| Philippe Magistretti | M | 68 |
University of Geneva
| 4 years |
| Nigel McCracken | M | - |
Debiopharm International SA
Debiopharm International SA Pharmaceuticals: MajorHealth Technology Debiopharm International SA operates as a biopharmaceutical development company with focus on biologics and drug evaluation, licensing and development. It formulates and develops products for the treatment of cancer, endometriosis, uterine fibroids and hepatitis. The company was founded in 1979 and is headquartered in Lausanne, Switzerland. | 5 years |
| Rajna Gibson Brandon | M | 61 |
University of Geneva
| 8 years |
| Manuel Leuthold | M | 64 |
University of Geneva
| 3 years |
| Henry Peter | M | 67 |
University of Geneva
| 7 years |
| Oengus Ramsay | M | - |
Debiopharm International SA
Debiopharm International SA Pharmaceuticals: MajorHealth Technology Debiopharm International SA operates as a biopharmaceutical development company with focus on biologics and drug evaluation, licensing and development. It formulates and develops products for the treatment of cancer, endometriosis, uterine fibroids and hepatitis. The company was founded in 1979 and is headquartered in Lausanne, Switzerland. | - |
| Nathalie Muller | F | - |
Debiopharm International SA
Debiopharm International SA Pharmaceuticals: MajorHealth Technology Debiopharm International SA operates as a biopharmaceutical development company with focus on biologics and drug evaluation, licensing and development. It formulates and develops products for the treatment of cancer, endometriosis, uterine fibroids and hepatitis. The company was founded in 1979 and is headquartered in Lausanne, Switzerland. | 3 years |
| Niklas Hallberg | M | - |
University of Geneva
| 3 years |
| Christine Deuschel Cornioley | M | - |
Debiopharm International SA
Debiopharm International SA Pharmaceuticals: MajorHealth Technology Debiopharm International SA operates as a biopharmaceutical development company with focus on biologics and drug evaluation, licensing and development. It formulates and develops products for the treatment of cancer, endometriosis, uterine fibroids and hepatitis. The company was founded in 1979 and is headquartered in Lausanne, Switzerland. | 23 years |
| Pierre Kairouz | M | - |
Debiopharm International SA
Debiopharm International SA Pharmaceuticals: MajorHealth Technology Debiopharm International SA operates as a biopharmaceutical development company with focus on biologics and drug evaluation, licensing and development. It formulates and develops products for the treatment of cancer, endometriosis, uterine fibroids and hepatitis. The company was founded in 1979 and is headquartered in Lausanne, Switzerland. | - |
| Pingzhong Huang | M | - |
University of Geneva
| 3 years |
| Frederic Henri Perrin | M | - |
University of Geneva
| 4 years |
| Jacky Vonderscher | M | 69 |
University of Geneva
| 3 years |
| Philippe Perles | M | 63 |
University of Geneva
| 4 years |
| Eric Alves de Souza | M | 63 |
University of Geneva
| 3 years |
| Carl G Bauer-Schlichtegroll | M | - |
University of Geneva
| 3 years |
| Barbara Lambert | F | 62 |
University of Geneva
| 4 years |
| Nada Soliman Shousha | F | 61 |
University of Geneva
| 4 years |
| Gregor Hubler | M | 56 |
University of Geneva
| 4 years |
| Frédéric Binder | M | 56 |
University of Geneva
| 3 years |
| Chris Freitag | M | 58 |
Debiopharm International SA
Debiopharm International SA Pharmaceuticals: MajorHealth Technology Debiopharm International SA operates as a biopharmaceutical development company with focus on biologics and drug evaluation, licensing and development. It formulates and develops products for the treatment of cancer, endometriosis, uterine fibroids and hepatitis. The company was founded in 1979 and is headquartered in Lausanne, Switzerland. | 2 years |
| Christine Gardiol | F | - |
University of Geneva
| 1 years |
| Luc Baatard | M | 67 |
University of Geneva
| 2 years |
| Nicolas Martin | M | - |
University of Geneva
| 4 years |
| Jean-Christophe Hocké | M | 55 |
University of Geneva
| 4 years |
| António Luís Guerra Nunes Mexia | M | 66 |
University of Geneva
| 4 years |
| Ravi Jhunjhunwala | M | 68 |
University of Geneva
| 1 years |
| Jean-Michel Richard | M | 61 |
University of Geneva
| 4 years |
| Kamel Besseghir | M | 75 |
Debiopharm International SA
Debiopharm International SA Pharmaceuticals: MajorHealth Technology Debiopharm International SA operates as a biopharmaceutical development company with focus on biologics and drug evaluation, licensing and development. It formulates and develops products for the treatment of cancer, endometriosis, uterine fibroids and hepatitis. The company was founded in 1979 and is headquartered in Lausanne, Switzerland. | 17 years |
| Andres McAllister | M | 68 |
Debiopharm International SA
Debiopharm International SA Pharmaceuticals: MajorHealth Technology Debiopharm International SA operates as a biopharmaceutical development company with focus on biologics and drug evaluation, licensing and development. It formulates and develops products for the treatment of cancer, endometriosis, uterine fibroids and hepatitis. The company was founded in 1979 and is headquartered in Lausanne, Switzerland. | 11 years |
| Martin Wienke | M | 59 |
University of Geneva
| 6 years |
| Bruno Barde | M | - |
University of Geneva
| 1 years |
| Andrea Broggini | M | 67 |
University of Geneva
| 3 years |
| Edoardo de Benedetti | M | 59 |
University of Geneva
| 3 years |
| Eiso Wortelboer | M | - |
University of Geneva
| 4 years |
| Giovanni M. Rossi | M | 55 |
University of Geneva
| 4 years |
| Hervé Porchet | M | - |
Debiopharm International SA
Debiopharm International SA Pharmaceuticals: MajorHealth Technology Debiopharm International SA operates as a biopharmaceutical development company with focus on biologics and drug evaluation, licensing and development. It formulates and develops products for the treatment of cancer, endometriosis, uterine fibroids and hepatitis. The company was founded in 1979 and is headquartered in Lausanne, Switzerland. | - |
| Choong Chang Lai | M | 57 |
University of Geneva
| 4 years |
| Massimo G. Pedrazzini | M | 61 |
University of Geneva
| 3 years |
| Patrick Aebischer | M | 70 |
University of Geneva
| 3 years |
| Bernard Schaub | M | 69 |
University of Geneva
| 3 years |
| Isabella De Michelis | F | - |
University of Geneva
| 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Switzerland | 49 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Houssam Ibrahim
- Personal Network
